Biodexa Pharmaceuticals (BDRX) Assets Average (2014 - 2025)

Biodexa Pharmaceuticals (BDRX) has 12 years of Assets Average data on file, last reported at $22.0 million in Q4 2025.

• For the quarter ending Q4 2025, Assets Average rose 20.1% year-over-year to $22.0 million; the trailing twelve-month figure through Dec 2025 stood at $22.0 million (up 20.1% YoY), and the FY2025 full-year result was $21.5 million, up 33.84% from the prior year.
• Assets Average rose to $22.0 million in Q4 2025, from $19.4 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $22.0 million in Q4 2025 to a low of $8.2 million in Q2 2023.
• A 5-year average of $15.2 million and a median of $15.1 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average tumbled 55.09% in 2021 and jumped 86.79% in 2024, its largest moves.
• Tracing BDRX's Assets Average over 5 years: stood at $12.3 million in 2021, then advanced by 20.67% to $14.8 million in 2022, then declined by 22.14% to $11.5 million in 2023, then jumped by 58.81% to $18.3 million in 2024, then grew by 20.1% to $22.0 million in 2025.
• Business Quant data shows BDRX's Assets Average at $22.0 million in Q4 2025, $19.4 million in Q2 2025, and $18.3 million in Q4 2024.